MYL

Mylan Inc. Press Releases

$57.325
*  
0.08
0.14%
Get MYL Alerts
*Delayed - data as of Feb. 27, 2015  -  Find a broker to begin trading MYL now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    MYL Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business
2/27/2015 12:30:00 PM - PR Newswire


Mylan Specialty to Present Findings from EpiPen4Schools® Program Survey
2/23/2015 10:45:00 AM - PR Newswire


Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India
2/23/2015 7:00:00 AM - PR Newswire


Mylan Schedules Fourth Quarter and Year End 2014 Financial Results Conference Call and Live Webcast
2/9/2015 11:45:00 AM - PR Newswire


Mylan Confirms First-to-File Patent Challenge Relating to NEXAVAR®
2/9/2015 11:00:00 AM - PR Newswire


Theravance Biopharma, Inc. and Mylan Partner to Develop and Commercialize a Novel LAMA Compound, TD-4208, for COPD
2/2/2015 7:00:00 AM - PR Newswire


Mylan to Acquire Famy Care Businesses to Create a Leading Women's Health Care Franchise
2/2/2015 6:44:00 AM - PR Newswire


Mylan Shareholders Overwhelmingly Approve Agreement Implementing Acquisition of Abbott's Non-U.S. Developed Markets Specialty and Branded Generics Business
1/29/2015 11:18:00 AM - PR Newswire


Mylan Expands Hepatitis C Licensing Agreement with Gilead to Include Investigational Pan-Genotypic Agent
1/26/2015 10:58:00 AM - PR Newswire
▲3.91 % Price Change since this news event. The Volume Ratio is 1.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


U.S. Supreme Court Partially Modifies Standard of Review of Patent Claim Construction and Remands Review of Teva''s ''808 Patent on Copaxone® to Federal Circuit Court of Appeals
1/20/2015 12:51:00 PM - PR Newswire
▲4.70 % Price Change since this news event. The Volume Ratio is 0.74.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Mylan Launches Generic Epivir-HBV® Tablets
1/15/2015 2:29:00 PM - PR Newswire
▲6.59 % Price Change since this news event. The Volume Ratio is 2.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Mylan Launches Generic Diovan® Tablets
1/5/2015 1:00:00 PM - PR Newswire
▲2.94 % Price Change since this news event. The Volume Ratio is 2.97.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


South African National Department of Health Selects Mylan as a Leading Supplier for 2015/2018 Antiretroviral Tender
12/31/2014 6:00:00 AM - PR Newswire
▲0.68 % Price Change since this news event. The Volume Ratio is 1.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Mylan Launches First Generic Version of Vivelle-DOT®
12/22/2014 7:30:00 AM - PR Newswire
▼-0.32 % Price Change since this news event. The Volume Ratio is 0.62.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference
12/17/2014 9:00:00 AM - PR Newswire
▲7.03 % Price Change since this news event. The Volume Ratio is 1.07.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Mylan Launches Generic Robaxin® Injection
12/11/2014 7:30:00 AM - PR Newswire
▲4.25 % Price Change since this news event. The Volume Ratio is 0.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Mylan Launches First Generic Version of Orapred ODT®
12/11/2014 7:00:00 AM - PR Newswire
▲4.25 % Price Change since this news event. The Volume Ratio is 0.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Mylan Launches One of First Available Generic Versions of Celebrex® Capsules
12/10/2014 7:30:00 AM - PR Newswire
▲1.33 % Price Change since this news event. The Volume Ratio is 1.28.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


World TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017
12/8/2014 5:01:00 AM - PR Newswire
▼-1.82 % Price Change since this news event. The Volume Ratio is 1.49.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
12/4/2014 11:29:00 AM - PR Newswire


Mylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
12/4/2014 10:00:00 AM - PR Newswire
▼-2.08 % Price Change since this news event. The Volume Ratio is 0.71.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day